rMBCG
PreclinicalBiologic
rMBCG is one of 51 biologic programs targeting Bladder Cancer. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
118 competitors in Bladder Cancer
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 3
Keytruda
Merck & Co.Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Tecentriq
RochePhase 3
Imfinzi
AstraZenecaPhase 3
Trexall
Jazz PharmaceuticalsPhase 3
Padcev
PfizerPhase 3
Imjudo
AstraZenecaPhase 3
Gemzar
GGynecologic Oncology Group
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for rMBCG. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- IImmunityBio, Inc.